Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

• Status: Recruiting
• Trial end date: 2023-10-25
• Target enrollment: 0
• Participant gender: All

Summary

The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infection. HIV-infected individuals have an increased risk for HPV infection, and persistent infection.

Most vaccine efficacy data among HIV-infected adolescents is represented by immunogenicity data, and there is little published literature on vaccine effectiveness as assessed by persistent incident genital HPV infection.

Investigators shall re-enroll a cohort of previously vaccinated HIV-infected girls and boys for assessment of genital HPV infection 9-years post initial 3 doses of vaccination with quadrivalent HPV vaccine at ages 9 to 14 years.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Washington
• Collaborator: Merck Sharp & Dohme LLC

Criteria

Inclusion Criteria:

• HIV-infected

• enrolled previously and received received three doses of quadrivalent HPV- vaccine in 2014

Exclusion Criteria:

• Decline re-enrollment

• unable to provide informed consent

• minor without parent or guardian consent